{"title":"美国食品和药物管理局（FDA）批准首个单药独立 MDD 治疗方案","authors":"Valerie A. Canady","doi":"10.1002/mhw.34313","DOIUrl":null,"url":null,"abstract":"<p>The Food and Drug Administration (FDA) last week approved the supplemental New Drug Application (sNDA) for spravato (esketamine), CII nasal spray considered the first and only monotherapy for adults with major depressive disorder (MDD) for adults who have failed to respond to at least two oral antidepressants.</p>","PeriodicalId":100916,"journal":{"name":"Mental Health Weekly","volume":"35 4","pages":"4-5"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FDA approves first monotherapy standalone MDD treatment\",\"authors\":\"Valerie A. Canady\",\"doi\":\"10.1002/mhw.34313\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The Food and Drug Administration (FDA) last week approved the supplemental New Drug Application (sNDA) for spravato (esketamine), CII nasal spray considered the first and only monotherapy for adults with major depressive disorder (MDD) for adults who have failed to respond to at least two oral antidepressants.</p>\",\"PeriodicalId\":100916,\"journal\":{\"name\":\"Mental Health Weekly\",\"volume\":\"35 4\",\"pages\":\"4-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mental Health Weekly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34313\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34313","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
FDA approves first monotherapy standalone MDD treatment
The Food and Drug Administration (FDA) last week approved the supplemental New Drug Application (sNDA) for spravato (esketamine), CII nasal spray considered the first and only monotherapy for adults with major depressive disorder (MDD) for adults who have failed to respond to at least two oral antidepressants.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
